Bradsaúde S.A (SAUD3) Fair Value & Analysis
Healthcare · BR · Market cap R$8.4B
Fair value as of: Aug 13, 2026
From 24 valuation models · updated today
Fair value updated Aug 13, 2026, revised from R$20.75 to R$17.73 (−14.6%) since Jul 16, 2026. Share price −10.6% over the past month.
A strong business, screening 29% undervalued on our models.
What matters now
- The rarer combination: high quality (87/100) AND below fair value. That earns a closer look rather than a quick verdict.
- A fairly wide model range (R$11.02 to R$27.60) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.
How to read this chart
60‑month range R$6.29 – R$16.09 · fair‑value band R$11.02 – R$27.60 · the R$13.72 price screens below the R$17.73 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Aug 13, 2026.
Analysis
Bradsaúde S.A (SAUD3) currently trades at R$13.72, while our model-based Fair Value estimate is R$17.73, implying the stock looks roughly 29.2% undervalued today. The Quality Score stands at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: high), always confirm before acting.
Over the trailing twelve months, Bradsaúde S.A generated revenue of R$2.6B at a net margin of 22.0%. Revenue grew 3.8% year over year. It earns a return on equity of 40.4%. The stock trades on a trailing P/E of 13.2. Fundamentals as of Aug 13, 2026
Our scenario range runs from R$11.02 (bear case) to R$27.60 (bull case); at R$13.72, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 17% below its 52-week high and 34% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -3% fair-value upside, at 29%, SAUD3 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth Earnings (R$21.23) versus Asset-Based (R$1.58). Highest evidence: Residual Income (76).
Notify me when SAUD3 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 82 · Market factors (momentum, volatility) 62
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bradsaúde S.A. provides private dental care plans in Brazil. The company operates through Corporate, Small and Medium-Sized Enterprise (SME), Individual, and Other segments. The company manages and sells dental care plans to corporations and/or individuals.
Full company description
Bradsaúde S.A. provides private dental care plans in Brazil. The company operates through Corporate, Small and Medium-Sized Enterprise (SME), Individual, and Other segments. The company manages and sells dental care plans to corporations and/or individuals. It is also involved in commercial advisory, consulting, and business management services; develops and licenses software programs; wholesale and retail trade of products and equipment, sanitizers, drugs, medicines, pharmaceutical inputs, and related items; provision of storage, loading, organization, tidying, custody of goods, technical, and administrative programming services, as well as general management of assets and business. In addition, the company engages in integrating technologies to develop dental solutions; and provide specialized services related to accidents and illnesses, besides actuarial, financial, administrative, and commercial and risk management services. The company was formerly known as Odontoprev S.A. and changed its name to Bradsaúde S.A. in April 2026. Bradsaúde S.A. was founded in 1987 and is headquartered in Barueri, Brazil. Bradsaúde S.A. operates as a subsidiary of Bradesco Saúde S.A.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2022 – FY2025 · reported fiscal years
Bradsaúde S.A reported revenue of R$2.4B in FY2025 versus R$1.9B in FY2022, a compound +9.3%/yr. Reported net income was R$583M in FY2025, compounding +16.8%/yr from FY2022.
Watch SAUD3: get an alert when its fair value changes →
Peer Group
Healthcare Plans · 15 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Healthcare Plans median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Healthcare Plans stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| UnitedHealth Group UNH | $405.59 | $292.06 | -28% |
| CVS Health Corporation CVS | $94.72 | $42.25 | -55% |
| Elevance Health, Inc ELV | $399.14 | $426.53 | +7% |
| The Cigna Group CI | $277.41 | $495.42 | +79% |
| Humana Inc HUM | $388.83 | $126.42 | -67% |
| Centene Corporation CNC | $67.07 | $111.96 | +67% |
| Molina Healthcare, Inc MOH | $206.06 | $199.31 | -3% |
| Oscar Health, Inc OSCR | $29.61 | $59.22 | +100% |
| Alignment Healthcare, Inc ALHC | $13.52 | $2.37 | -82% |
| Progyny, Inc PGNY | $25.42 | $16.44 | -35% |
Compare Bradsaúde S.A with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bradsaúde S.A (SAUD3) overvalued or undervalued?
What is the fair value of SAUD3?
What is the quality score of SAUD3?
What is the revenue of Bradsaúde S.A (SAUD3)?
What is the net profit margin of SAUD3?
Does Bradsaúde S.A pay a dividend?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bradsaúde S.A and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.